✦ LIBER ✦

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome

✍ Scribed by Steg, P. G.; Mehta, S. R.; Jukema, J. W.; Lip, G. Y. H.; Gibson, C. M.; Kovar, F.; Kala, P.; Garcia-Hernandez, A.; Renfurm, R. W.; Granger, C. B.

Book ID: 125530333
Publisher: Oxford University Press
Year: 2011
Tongue: English
Weight: 375 KB
Volume: 32
Category: Article
ISSN: 0195-668X
DOI: 10.1093/eurheartj/ehr334

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rationale and design of the Anti-Xa Ther

Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome

✍ C. Michael Gibson; Jessica L. Mega; Paul Burton; Shinya Goto; Freek Verheugt; Ch 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 428 KB